2020 AAN Annual Meeting, Toronto, Canada – canceled due to COVID-19

GenSight Biologics Announces Positive Data Safety Monitoring Board Review of PIONEER Phase I/II Trial of GS030 Combining Gene Therapy and Optogenetics for the Treatment of Retinitis Pigmentosa

GenSight Biologics Provides Update on Operations in the Context of COVID-19

GenSight Biologics announces presentation of bilateral visual recovery from GS010 (LUMEVOQ™) Phase III trials at the 46th annual meeting of NANOS

46th NANOS Annual Meeting, Amelia Island, Florida, US

GenSight Biologics reports findings from REALITY study and REVERSE-RESCUE analysis highlighting positive benefits from LUMEVOQ™ (GS010) compared to LHON natural history

The Quinze-Vingts Hospital and GenSight Biologics announce a first Temporary Authorization for Use (ATU) for LUMEVOQ™ (GS010) in France

ESGCT 27th Annual Congress, Barcelona (Spain)

EVER 2019, Nice (FR)

3rd Annual Gene Therapy for Rare Disorders Europe, London (UK)